Zhi‐Wei Lai

<i>N</i> ‐acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double‐blind, placebo‐controlled trial

Zhi‐Wei Lai, Robert Hanczko, Eduardo Bonilla et al. · Arthritis & Rheumatism · 2012 · 411 citations

Life Sciences, Immunology, Pharmacology +17

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

Zhi‐Wei Lai, Ryan L. Kelly, Thomas Winans et al. · The Lancet · 2018 · 401 citations

Life Sciences, Pharmacology, Pharmacotherapy +11

Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin

András Perl, Robert Hanczko, Zhi‐Wei Lai et al. · Metabolomics · 2015 · 187 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE

Tiffany Caza, David Fernández, Gergely Talabér et al. · Annals of the Rheumatic Diseases · 2013 · 187 citations · Full text

Medicine, Internal Medicine, Clinical Medicine +6

Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus

Zhi‐Wei Lai, Rebecca Borsuk, Ashwini Shadakshari et al. · The Journal of Immunology · 2013 · 157 citations

Life Sciences, Cell Biology, Immunology +17